Vir Biotechnology, Inc. VIR Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s accrued expenses and other liabilities?
- Vir Biotechnology, Inc. (VIR) reported accrued expenses and other liabilities of $68.11M in Q1 2026.
- How has Vir Biotechnology, Inc.'s accrued expenses and other liabilities changed year-over-year?
- Vir Biotechnology, Inc.'s accrued expenses and other liabilities decreased by 34.6% year-over-year, from $104.13M to $68.11M.
- What is the long-term trend for Vir Biotechnology, Inc.'s accrued expenses and other liabilities?
- Over 5 years (2020 to 2025), Vir Biotechnology, Inc.'s accrued expenses and other liabilities has grown at a 1.5% compound annual growth rate (CAGR), from $76.94M to $83.01M.